Scholarlink

Background <p>The evidence considering the potential protective impact of statins on the mortality rate caused by colorectal cancer (CRC) is controversial. This study aimed to systematically assess the effect of statins on the survival rate of CRC patients.</p> Methods <p>A comprehensive search was conducted in Scopus, PubMed, and Web of Science to assess the relationship between statin consumption and cancer-specific mortality (CSM), all-cause mortality (ACM), disease-free survival (DFS), and recurrence-free survival (RFS). Subgroup analyses were performed to assess data stratified by country, study design, disease stage, time to use, CRC, and treatment type due to high heterogeneity.</p> Results <p>Thirty-two studies were included; the data of 24 articles composed the meta-analysis. Statins improved prognosis of CRC, particularly in lower ACM (HR: 0.80; 95% CI: 0.74–0.87) with I²=90%, <i>P</i>-value &lt; 0.01, and lower CSM (HR: 0.74; 95% CI: 0.67–0.82) with I²=88%, <i>P</i>-value &lt; 0.01 when compared to non-users. Both pre- and post-diagnostic statin use were linked to lower ACM and CSM, though high heterogeneity was observed across studies. However, the results for statin use on RFS indicated an HR of 1.01 with 95% CI of 0.94 to 1.09 (I² = 0% and <i>P</i>-value = 0.93). Additionally, for DFS, the HR was 0.93 (95% CI: 0.85–1.01) with I² = 47%, suggesting no meaningful effect of statin use on DFS. No significant publication bias was found.</p> Conclusion <p>Statin use was associated with a reduction in ACM and CSM in CRC patients. However, the variances in RFS and DFS were not statistically significant. However, these findings should be interpreted cautiously due to substantial heterogeneity among some included studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The impact of statin use on colorectal cancer prognosis: a systematic review and meta-analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月9日

查看全文
  • Iman Elahi Vahed,
  • Amir mohammad Rishialiabad,
  • Fatemeh Moeinaddini,
  • Amir Hosein Shabani,
  • Asal Kazemzadeh,
  • Mojtaba Esmaeeli,
  • Mostafa Neshat Ghalibaf,
  • Mahdiyeh Nozad Varjovi,
  • Maryam Shirmohamadi,
  • Mohaddese Heydari,
  • Parsa Tavassoli Naini,
  • Mohammadsadegh Jafari,
  • Alireza Gholami,
  • Hossein Soltaninejad,
  • Mohammad Rahmanian

摘要

Background

The evidence considering the potential protective impact of statins on the mortality rate caused by colorectal cancer (CRC) is controversial. This study aimed to systematically assess the effect of statins on the survival rate of CRC patients.

Methods

A comprehensive search was conducted in Scopus, PubMed, and Web of Science to assess the relationship between statin consumption and cancer-specific mortality (CSM), all-cause mortality (ACM), disease-free survival (DFS), and recurrence-free survival (RFS). Subgroup analyses were performed to assess data stratified by country, study design, disease stage, time to use, CRC, and treatment type due to high heterogeneity.

Results

Thirty-two studies were included; the data of 24 articles composed the meta-analysis. Statins improved prognosis of CRC, particularly in lower ACM (HR: 0.80; 95% CI: 0.74–0.87) with I²=90%, P-value < 0.01, and lower CSM (HR: 0.74; 95% CI: 0.67–0.82) with I²=88%, P-value < 0.01 when compared to non-users. Both pre- and post-diagnostic statin use were linked to lower ACM and CSM, though high heterogeneity was observed across studies. However, the results for statin use on RFS indicated an HR of 1.01 with 95% CI of 0.94 to 1.09 (I² = 0% and P-value = 0.93). Additionally, for DFS, the HR was 0.93 (95% CI: 0.85–1.01) with I² = 47%, suggesting no meaningful effect of statin use on DFS. No significant publication bias was found.

Conclusion

Statin use was associated with a reduction in ACM and CSM in CRC patients. However, the variances in RFS and DFS were not statistically significant. However, these findings should be interpreted cautiously due to substantial heterogeneity among some included studies.